A Phase Ia Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345 in Patients With CLDN18.2-positive Solid Tumors

Study Summary

A phase Ia study to evaluate the safety, tolerance, pharmacokinetics and preliminary efficacy of IBI345 in patients with CLDN18.2 positive solid tumors

Interventions

Study Locations

Facility	City	State	Country
The First Affiliated Hospital of Soochow University	Suzhou	Jiangsu	China

Official Trial Information

View on ClinicalTrials.gov